

SUPPLEMENTARY TABLES

Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals

Neelakshi R. Jog¹, Kendra A. Young², Melissa E. Munroe¹, Michael T. Harmon¹, Joel M. Guthridge¹, Jennifer A. Kelly¹, Diane L. Kamen³, Gary S. Gilkeson³, Michael H. Weisman⁴, David R. Karp⁵, Patrick M. Gaffney¹, John B. Harley^{6,7,8}, Daniel J. Wallace⁴, Jill M. Norris², Judith A. James^{1,9}

¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

²Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

³Department of Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA

⁴Division of Rheumatology, Cedar-Sinai Medical Center, Los Angeles, CA, USA

⁵Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA

⁶Center of Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

⁷Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA

⁸US Department of Veterans Affairs Medical Center, Cincinnati, OH, USA

⁹Departments of Medicine and Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA

Correspondence: Judith A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, Phone: 405-271-4987, Fax: (405) 271-7063, Email: judith-james@omrf.org

Short title: EBV sero-reactivation in lupus transition

Supplementary Table 1. Increasing VCA IgG levels and EA IgG levels correlate with both increasing number of autoantibodies and ACR criteria

	Number of AutoAb	ACR score
	R (p value)	R (p value)
VCA IgG OD ratio	0.15 (0.002)	0.15 (0.002)
VCA IgA OD ratio	0.08 (0.08)	0.008 (0.086)
EA IgG OD ratio	0.22 (<0.0001)	0.15 (0.001)

Supplementary Table 2. Significant interactions were found between variants in IL10 and VCA IgA ISR and variants in CD40 and VCA IgG ISR in the risk of transitioning to SLE. ^a

Gene	SNP	Antibody	Transitioned vs.	Transitioned vs.	Non Transition
			Non Transition relatives N=406 OR (95% CI) p-value	Unaffected Controls N=167 OR (95% CI) p-value	vs. Unaffected Controls N=470 OR (95% CI) p-value
IL10	rs3024505	VCA-IgG	0.29	0.05	0.34
IL10	rs3024505	VCA-IgA	0.01	0.047	0.82
IL10	rs3024505	EA	0.35	0.60	0.82
IL10	rs3024495	VCA-IgG	0.35	0.05	0.24
IL10	rs3024495	VCA-IgA	0.03	0.11	0.77
IL10	rs3024495	EA	0.22	0.59	0.86
IL10	rs3024493	VCA-IgG	0.22	0.04	0.36
IL10	rs3024493	VCA-IgA	0.008	0.04	0.81
IL10	rs3024493	EA	0.18	0.40	0.66
IL10	rs1800896	VCA-IgG	0.45	0.10	0.31
IL10	rs1800896	VCA-IgA	0.55	0.92	0.65
IL10	rs1800896	EA	0.30	0.24	0.14
IL10	rs3122605	VCA-IgG	0.05	0.12	0.63
IL10	rs3122605	VCA-IgA	0.02	0.005	0.41
IL10	rs3122605	EA	0.70	0.97	0.81
CD40	rs1569723	VCA-IgG	0.01	0.04	0.58
CD40	rs1569723	VCA-IgA	0.16	0.69	0.40

CD40	rs1569723	EA	0.10	0.21	0.12
CD40	rs1883832	VCA-IgG	0.003	0.008	0.84
CD40	rs1883832	VCA-IgA	0.46	0.79	0.71
CD40	rs1883832	EA	0.09	0.40	0.22
CD40	rs4810485	VCA-IgG	0.0009	0.01	0.48
CD40	rs4810485	VCA-IgA	0.64	0.91	0.54
CD40	rs4810485	EA	0.12	0.52	0.28
CR2	rs17615	VCA-IgG	0.55	0.85	0.25
CR2	rs17615	VCA-IgA	0.03	0.06	0.83
CR2	rs17615	EA	0.99	0.25	0.67

^a Odds Ratio (OR) presented for 1 unit increase in OD ratio